VCM
TEVA icon

Versant Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Versant Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Buy
10,265
+1,399
+16% +$46.6K 0.03% 421
2026
Q1 		$267K Buy
8,866
+1,932
+28% +$62.2K 0.03% 483
2025
Q4 		$216K Buy
6,934
+1,374
+25% +$33.8K 0.03% 465
2025
Q3 		$112K Buy
5,560
+981
+21% +$17.2K 0.02% 668
2025
Q2 		$76.7K Sell
4,579
-718
-14% -$11.6K 0.01% 786
2025
Q1 		$81.4K Buy
5,297
+4,312
+438% +$77K 0.01% 697
2024
Q4 		$21.7K Buy
985
+760
+338% +$13.8K ﹤0.01% 987
2024
Q3 		$4.05K Buy
+225
New +$3.94K ﹤0.01% 1360

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Versant Capital Management's TEVA Position: Q2 2026 in Review

Versant Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 16% in Q2 2026, buying an estimated $46.6K and bringing the position to 10,265 shares worth $348K. The position accounts for 0.03% of the portfolio, ranked #421.

Versant Capital Management first reported a position in TEVA in Q3 2024 and has held it in 8 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Versant Capital Management held 10,265 shares of Teva Pharmaceuticals worth $348K as of Q2 2026.
  • Versant Capital Management bought 1,399 Teva Pharmaceuticals shares in Q2 2026, an estimated $46.6K.
  • Teva Pharmaceuticals made up 0.03% of Versant Capital Management's portfolio in Q2 2026, its #421 holding.
  • Versant Capital Management first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.